AACHEN, Germany, May 22, 2013 /PRNewswire/ --
Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new website answers questions like "Why is PHN often misdiagnosed?" "Which questions help making the correct diagnosis?" and "What are effective, well tolerated and easy-to-use first-line treatment options?" Please visit http://www.versatis.com for details.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of € 973 mn. More information: http://www.grunenthal.com.
Embargo: This information is intended for healthcare professionals only.
Contact: Jeanette Hübsch, Senior Manager Versatis, Grünenthal Europe & Australia
Phone: +49-241-569-1487, email: [email protected]
SOURCE Grünenthal GmbH